Organization | United States Navy

United States Navy Report issue

Government Phase 1 Phase 2 Phase 3 Phase 4

Founded: Arlington VA United States (1775)

Organization Overview

First Clinical Trial

1998

NCT02488902

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

CUBRC, MTEC, and US Navy | Enteric Disease Department, Naval Medical Research Center | Enteric Diseases Department Naval Medical Research Center | Enteric Diseases Department, Naval Medical Research Center | National Naval Medical Center | National Naval Medical Center, Bethesda | Naval Aeromedical Research Unit, Dayton | Naval Health Research Center | Naval Health Research Center - San Diego | Naval Hospital Camp Lejeune | Naval Hospital Camp Pendleton | NavalMCSD Pain Center | Naval Medical Center Camp Lejeune | Naval Medical Center San Diego Department of Orthopadic Surgery | Naval Medical Research Center | Naval Medical Research Center, Asia (NMRC-A) | Naval Medical Research Center (NMRC) | Naval Medical Research Unit- 3 | Naval Medical Research Unit- 6 | Naval Medical Research Unit - Dayton | Naval Medical Research Unit No 6 | Naval Officer, Naval Medical Center - Portsmouth | Navy Advanced Medical Development (NAMD) Command | Navy Bureau of Medicine and Surgery | Navy General Hosiptal | Navy Medical Center San Diego | Navy Medical Center, San Diego | Navy Medical Research Center | Navy Warfighter Refractive Surgery San Diego | NMCSD | NMRTC Bethesda | Office of Naval Research (ONR) | United States Naval Medical Center, Portsmouth | United States Naval Medical Center, San Diego | United States Naval Medical Center, San Diego,CA | United States Navy | US Military Vaccine Program, NMRC PI, Naval Officer | US Naval Medical Research Unit | U.S. Naval Medical Research Unit No. 3 | US Navy | U.S. Navy Bureau of Medicine | Virology and Rickettsial Diseases Department, Naval Medical Research Center

Active Ingredients

Drugs in Phase 4 Trials (15)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (2 trials)

artesunate (2 trials)

atovaquone (mepron) (2 trials)

corticotropin (acthar) (1 trial)

dexamethasone (1 trial)

diphenhydramine (benadryl) (2 trials)

fluorometholone (fml) (2 trials)

gabapentin (neurontin) (2 trials)

haloperidol (haldol) (1 trial)

imiquimod (aldara) (3 trials)

inactivated influenza vaccine (1 trial)

mefloquine (lariam) (2 trials)

metoclopramide (reglan) (1 trial)

proguanil (2 trials)

tranexamic acid (cyklokapron) (1 trial)

Drugs in Phase 3 Trials (21)

alfuzosin (uroxatral) (1 trial)

doxazosin (cardura) (1 trial)

etanercept (enbrel) (1 trial)

goserelin (zoladex) (1 trial)

incobotulinumtoxinA (Xeomin) (1 trial)

ketamine (ketalar) (4 trials)

killed enterotoxigenic escherichia coli vaccine (1 trial)

leuprolide (lupron) (1 trial)

levobupivacaine (chirocaine) (2 trials)

melatonin (1 trial)

methylprednisolone (medrol) (1 trial)

mitomycin (mutamycin) (1 trial)

nifedipine (procardia) (1 trial)

onabotulinumtoxinA (Botox) (1 trial)

pneumococcal 7-valent conjugate vaccine (prevnar) (1 trial)

prazosin (minipress) (1 trial)

scopolamine (transderm scop) (2 trials)

sodium chloride (4 trials)

thalidomide (Thalomid) (1 trial)

vancomycin (Vancocin) (1 trial)

Drugs in Phase 2 Trials (23)

acetaminophen (tylenol) (2 trials)

adenovirus-vectored malaria vaccines encoding plasmodium falciparum circumsporozoite protein and apical membrane antigen 1 (1 trial)

anti-cs17 bovin igg (1 trial)

anti-csbd bovine igg (1 trial)

autologous bone marrow (1 trial)

carbon dioxide (dry ice) (1 trial)

dna-ad vaccine (1 trial)

fisetin (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

ibuprofen (motrin) (3 trials)

invaplex 50 vaccine (1 trial)

lmn-101 (1 trial)

losartan (cozaar) (1 trial)

mirabegron (myrbetriq) (1 trial)

nitroglycerin (transderm-nitro) (1 trial)

nmrc-m3v-ad-pfca (2 trials)

nmrc-mv-ad-pfa (1 trial)

nmrc-mv-ad-pfc (1 trial)

oxytocin (syntocinon) (2 trials)

pfspz vaccine (2 trials)

platelet rich plasma (2 trials)

tafenoquine succinate (arakoda) (1 trial)

vla1701 (1 trial)

Drugs in Phase 1 Trials (28)

aluminum hydroxide (Gaviscon) (1 trial)

amnion-derived cellular cytokine (1 trial)

anti-cfae bovine igg (1 trial)

anti-cfa/i bovine igg (1 trial)

b7a bsigg (1 trial)

bovine immunoglobin (1 trial)

campylobacter jejuni strain bh-01-0142 (1 trial)

campylobacter jejuni strain cg8421 (2 trials)

cellulose (1 trial)

cjcv1 (1 trial)

d1me100 (1 trial)

d/chad63-cat (1 trial)

detoxified shigella flexneri 2a artificial invasin complex (1 trial)

dsccfae (2 trials)

etec vaccine (2 trials)

fimbrial adhesin (1 trial)

flexyn2a (1 trial)

live, attenuated, dengue serotype 1, 2, 3, 4 virus (1 trial)

mecs6 (1 trial)

modified e. coli heat labile enterotoxin ltr192g (2 trials)

multikine (2 trials)

plasmodium falciparum sporozoite (1 trial)

r192g (1 trial)

rfla-mbp (1 trial)

shigella flexneri 2a invaplex 50 (2 trials)

tetravalent dengue vaccine (1 trial)

zanamivir (relenza) (1 trial)

Drugs in Other Trials (28)

anti-influenza plasma (1 trial)

apple cider vinegar (1 trial)

azithromycin (zithromax) (1 trial)

bupivacaine (Exparel) (1 trial)

caffeine (1 trial)

chlorhexidine (hibitane) (1 trial)

citalopram (celexa) (1 trial)

clindamycin (cleocin) (1 trial)

gentamicin (garamycin) (1 trial)

inulin (1 trial)

iohexol (Omnipaque) (1 trial)

levofloxacin (levaquin) (1 trial)

lidocaine (xylocaine) (1 trial)

loperamide (imodium) (1 trial)

maltodextrin (1 trial)

neural progenitor cell (1 trial)

ondansetron (zofran) (1 trial)

paracrine factor of human mesenchymal stem cells (1 trial)

paracrine factors (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

prochlorperazine (compazine) (1 trial)

progenitor cell (1 trial)

propofol (diprivan) (1 trial)

rifaximin (xifaxan) (2 trials)

ropivacaine (naropin) (1 trial)

sertraline (zoloft) (1 trial)

sumatriptan (zecuity) (1 trial)

triamcinolone (kenalog) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Altitude Sickness (Phase 2)

Biliary Tract Diseases (Phase 2)

Calculi (Phase 3)

Campylobacter Infections (Phase 2)

Carcinoma in Situ (Phase 3)

Cervical Intraepithelial Neoplasia (Phase 3)

Cholecystolithiasis (Phase 2)

Cholelithiasis (Phase 2)

Condylomata Acuminata (Phase 1)

Corneal Opacity (Phase 3)

Dengue (Phase 1)

Depression (Phase 3)

Depressive Disorder (Phase 1)

Diarrhea (Phase 3)

Disease (Phase 3)

Dry Eye Syndromes (Phase 1)

Dysentery (Phase 1)

Dysentery, Bacillary (Phase 2)

Emergencies (Phase 4)

Escherichia coli Infections (Phase 2)

Fibrosis (Phase 2)

Gallstones (Phase 2)

Headache (Phase 4)

Hemorrhage (Phase 4)

Hernia (Phase 4)

Hernia, Inguinal (Phase 4)

Hyperplasia (Phase 4)

Infections (Phase 1)

Influenza, Human (Phase 4)

Keratoconjunctivitis Sicca (Phase 1)

Kidney Calculi (Phase 3)

Malaria (Phase 4)

Malaria, Falciparum (Phase 4)

Migraine Disorders (Phase 4)

Motion Sickness (Phase 3)

Nausea (Phase 3)

Neoplasms (Phase 3)

Nephrolithiasis (Phase 3)

Osteoarthritis (Phase 3)

Osteoarthritis, Hip (Phase 2)

Osteoarthritis, Knee (Phase 3)

Papilloma (Phase 4)

Peripheral Nervous System Diseases (Phase 4)

Phantom Limb (Phase 4)

Pneumonia (Phase 4)

Post-Dural Puncture Headache (Phase 4)

Postpartum Hemorrhage (Phase 4)

Prostatic Neoplasms (Phase 3)

Psychomotor Agitation (Phase 4)

Radiculopathy (Phase 3)

Respiration Disorders (Phase 4)

Respiratory Tract Diseases (Phase 4)

Shoulder Injuries (Phase 3)

Shoulder Pain (Phase 3)

Skin Neoplasms (Phase 1)

Suicide (Phase 3)

Tendinopathy (Phase 3)

Ureteral Calculi (Phase 3)

Ureterolithiasis (Phase 3)

Warts (Phase 1)

Wounds and Injuries (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 94
# of Trial APIs: 115